Your browser doesn't support javascript.
loading
High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.
Agolory, Simon G; Auld, Andrew F; Odafe, Solomon; Shiraishi, Ray W; Dokubo, E Kainne; Swaminathan, Mahesh; Dalhatu, Ibrahim; Onotu, Dennis; Abiri, Oseni; Debem, Henry; Bashorun, Adebobola; Ellerbrock, Tedd V.
Afiliação
  • Agolory SG; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
  • Auld AF; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
  • Odafe S; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
  • Shiraishi RW; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
  • Dokubo EK; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
  • Swaminathan M; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Atlanta, United States of America.
  • Dalhatu I; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
  • Onotu D; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
  • Abiri O; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
  • Debem H; School of Biomedical Informatics, University of Texas, Houston, United States of America.
  • Bashorun A; Division of Global HIV & TB, U.S. Centers for Disease Control & Prevention, Abuja, Nigeria.
  • Ellerbrock TV; National AIDS & STIs Control Program, Federal Ministry of Health, Abuja, Nigeria.
PLoS One ; 12(9): e0183823, 2017.
Article em En | MEDLINE | ID: mdl-28863160
ABSTRACT

BACKGROUND:

With about 3.4 million HIV-infected persons, Nigeria has the second highest number of people living with HIV (PLHIV) in the world. However, antiretroviral treatment (ART) coverage in Nigeria remains low with only 748,846 (22%) of PLHIV on ART by the end of 2014. Retention of HIV-infected patients in pre-ART care is essential to ensure timely ART initiation. We assessed outcomes of patients enrolled in Nigeria's pre-ART program during 2004-2012.

METHODS:

We conducted a nationally representative retrospective cohort study among adults (≥15 years old), enrolling in pre-ART programs supported by the U.S. President's Emergency Plan for AIDS Relief in Nigeria. A total of 35 sites enrolling ≥50 patients in pre-ART were selected using probability proportional-to-size sampling; 2,415 eligible medical records at these sites were randomly selected for abstraction. Determinants of loss to follow-up (LTFU) and mortality during pre-ART care were estimated using Cox proportional hazards regression models.

RESULTS:

The median age at enrollment was 32 years (interquartile range (IQR) 27-40). A total of 1,216 (51.4%) initiated ART by the time of data abstraction. Among the remaining 1,199 patients, 898 (74.9%) had been LTFU, 180 (15.0%) were alive and in pre-ART care, 71 (5.9%) had died, 50 (4.2%) had transferred out or stopped care. Baseline markers of advanced disease, including weight <45 kg (adjusted hazard ration (AHR) = 4.23; 95% confidence interval (CI) 1.51-15.58) and more advanced WHO disease stage, were predictive of pre-ART mortality. Compared with patients aged 15-24, patients aged 35-44 (AHR = 0.67; 95% CI 1.0.47-0.95) and age 45-54 (AHR = 0.66; 95% CI 0.48-0.91) had lower LTFU rates. Compared with attending facilities in North Central geopolitical zone, attending facility locations in South East (AHR = 0.44; 95% CI 0.24-0.83) was protective against LTFU.

CONCLUSIONS:

About half of patients enrolling in HIV program during 2004-2012 in Nigeria had not initiated ART by 2013. Key strategies to improve early ART initiation among pre-ART enrollees include implementation of the WHO test and treat guidelines, earlier HIV testing, and better monitoring to improve ART initiation rates. Further research to understand regional variations in pre-ART outcomes is warranted.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Antirretrovirais / Perda de Seguimento Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Antirretrovirais / Perda de Seguimento Idioma: En Ano de publicação: 2017 Tipo de documento: Article